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Abstract
During hematogenously disseminated disease, Candida albicans infects most organs, including the brain. We discovered
that a C. albicans vps51D/D mutant had significantly increased tropism for the brain in the mouse model of disseminated
disease. To investigate the mechanisms of this enhanced trafficking to the brain, we studied the interactions of wild-type C.
albicans and the vps51D/D mutant with brain microvascular endothelial cells in vitro. These studies revealed that C. albicans
invasion of brain endothelial cells is mediated by the fungal invasins, Als3 and Ssa1. Als3 binds to the gp96 heat shock
protein, which is expressed on the surface of brain endothelial cells, but not human umbilical vein endothelial cells, whereas
Ssa1 binds to a brain endothelial cell receptor other than gp96. The vps51D/D mutant has increased surface expression of
Als3, which is a major cause of the increased capacity of this mutant to both invade brain endothelial cells in vitro and traffic
to the brain in mice. Therefore, during disseminated disease, C. albicans traffics to and infects the brain by binding to gp96,
a unique receptor that is expressed specifically on the surface of brain endothelial cells.
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Introduction
Hematogenously disseminated candidiasis is a serious disease
that remains associated with approximately 35% mortality, even
with currently available treatment, and Candida albicans is the
infecting organism in approximately 50% of patients [1,2]. During
this disease, C. albicans is carried by the bloodstream to virtually all
organs of the body, including the brain. Although candidal
infection of the brain may not be clinically evident in adults with
disseminated candidiasis, it is frequently found at autopsy in
patients who die of this disease [3]. Even more importantly,
candidal brain infection, especially meningitis, is a significant
problem in premature infants who have risk factors for
disseminated candidiasis, even in the absence of detectable
candidemia [4,5].
To invade the brain parenchyma, blood-borne C. albicans cells
must adhere to and traverse the endothelial cell lining of the blood
vessels within the central nervous system. Brain endothelial cells
are significantly different from those lining systemic blood vessels.
For example, they have tight junctions that are not present in the
endothelial cells in other vascular beds. Forming the blood brain
barrier, brain endothelial cells restrict the diffusion of large or
hydrophilic molecules into the central nervous system, while
allowing the diffusion of small hydrophobic molecules [6]. More
importantly, some microbial pathogens, such as Neisseria meningi-
tidis, Streptococcus pneumonia, Escherichia coli K1, and Cryptococcus
neoformans have an enhanced capacity to adhere to and invade
human brain microvascular endothelial cells (HBMECs), which
enables them to preferentially infect the central nervous system via
the hematogenous route [7–11]. Thus, these pathogens can exploit
the unique characteristics of HBMECs to specifically infect the
brain.
Studies using human umbilical vein endothelial cells (HUVECs)
as representative systemic endothelial cells have demonstrated that
C. albicans adheres to, invades, and damages these cells in vitro
[12,13]. One mechanism by which C. albicans invades these cells is
by stimulating its own endocytosis, which is induced when the C.
albicans invasins, Als3 and Ssa1, bind to receptors such as N-
cadherin and HER2 on the endothelial cell surface [14–17]. C.
albicans yeast and hyphae can also invade HBMECs by inducing
their own endocytosis [18,19]. However, the mechanism by which
this pathogen invades these endothelial cells and infects the brain
is poorly understood.
Recently we discovered that C. albicans VPS51 is up-regulated by
contact with HUVECs in vitro, and that a vps51/vps51 insertion
mutant is defective in damaging these endothelial cells [20]. In
Saccharomyces cerevisiae, Vps51 is known to bind to the Vps52/53/54
complex and is required for the retrograde transport of proteins
from endosomes to the late Golgi [21,22]. Although the function
of Vps51 in C. albicans has not been studied in detail, the vps51/
vps51 insertion mutant has a fragmented vacuole, similar to the
corresponding S. cerevisiae mutant [20–22]. Thus, Vps51 likely
plays a role in protein trafficking in C. albicans.
In the current study, we investigated how deletion of VPS51
affects the virulence of C. albicans during hematogenous infection.
We found that the vps51D/D null mutant exhibits a preferential
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enhanced exposure of Als3 on the surface of the vps51D/D mutant,
which binds to gp96 on the surface of HBMECs and mediates
invasion of these endothelial cells. We further discovered that gp96
functions as a receptor for wild-type C. albicans on HBMECs, but
not HUVECs, indicating that this organism invades the central
nervous system by binding to a receptor that is expressed
specifically on HBMECs.
Results
Deletion of VPS51 causes reduced mortality and
decreased kidney and liver fungal burden during
hematogenously disseminated candidiasis
To investigate the role of Vps51 in the virulence of C. albicans,
we inoculated mice via the lateral tail vein with a wild-type strain,
a vps51D/D mutant, and a vps51D/D+pVPS51 complemented
strain and then monitored their survival over time. We found that
all mice infected with the vps51D/D mutant survived for the entire
21-day observation period, whereas all mice infected with the wild-
type strain died within 7 days after inoculation (Figure 1A).
Complementing the vps51D/D mutant with an intact copy of
VPS51 restored its virulence to wild-type levels, thus confirming
that Vps51 is required for the maximal virulence of C. albicans. The
greatly reduced virulence of the vps51D/D mutant was further
verified by infecting mice with a 6-fold higher inoculum. As
expected, mice infected with the wild-type strain at this higher
inoculum died rapidly, with a median survival of only 3 days
(Figure 1B). However, all mice infected with the vps51D/D mutant
still survived. Therefore, Vps51 is necessary for the full virulence of
C. albicans.
The mouse model of hematogenous disseminated candidiasis
mimics many aspects of this disease in humans, particularly the
formation of microabscesses in most organs [23,24]. We therefore
investigated the effects of deleting VPS51 on organ fungal burden.
During the first 4 days of infection, the kidneys and livers of mice
infected with the vps51D/D mutant contained significantly fewer
organisms than those of mice infected with either the wild-type or
vps51D/D+pVPS51 complemented strain (Figure 1C and D).
Furthermore, the kidney fungal burden of mice infected with the
vps51D/D mutant progressively declined after the first day of
infection. In contrast, the kidney fungal burden of mice infected
with the wild-type and vps51D/D+pVPS51 complemented strains
progressively increased for the first 4 days post-infection, after
which these mice began to die. These results further demonstrate
that the overall virulence of the vps51D/D mutant is decreased.
Absence of Vps51 or Vps53 results in increased brain
fungal burden
A surprising result was that during the first 4 days of infection,
the brain fungal burden of mice infected with the vps51D/D
mutant was significantly greater than that of mice infected with
either the wild-type or vps51D/D+pVPS51 complemented strain
(Figure 1E). Indeed, after 3 days of infection, the brains of mice
infected with the vps51D/D mutant contained a median of 50-fold
more organisms than those of mice infected with the wild-type
strain. Despite having a high brain fungal burden, the mice
infected with the vps51D/D mutant did not appear to be sick and
had no obvious signs of neurological disease. Moreover, beginning
on the fourth day of infection, these mice progressively cleared the
organisms from their central nervous system. These results suggest
that while the overall virulence of the vps51D/D mutant is
decreased, it has a distinct tropism for the brain.
We verified these quantitative culture results by performing
histopathologic analysis of the brains of the infected mice. Foci
containing multiple organisms were visible in the brains of mice
infected with the vps51D/D mutant, especially in the hippocampus
(Figure 1F). In sharp contrast, only rare organisms were visible in
the brains of the mice infected with either the wild-type or vps51D/
D+pVPS51 complemented strains, and these organisms were
typically either solitary or in pairs.
To determine if another member of the Vps51/52/53/54
complex is required for maximal virulence and enhanced brain
tropism, we constructed and analyzed a vps53D/D mutant. This
strain also caused no mortality in mice following tail vein
inoculation. (Figure 2A) Furthermore, it accumulated at signifi-
cantly higher levels in the brain than did the wild-type and
vps53D/D+pVPS53 complemented strains (Figure 2B). Collective-
ly, these results demonstrate that the Vps51/52/53/54 complex
plays a key role in virulence, and that C. albicans strains that lack
components of this complex preferentially infect the brain.
The vps51D/D mutant has an increased capacity to
adhere to and invade HBMECs
To cross the endothelial cell lining of the vasculature, C. albicans
must first adhere to these endothelial cells and then invade
through them. We hypothesized that the vps51D/D mutant had
increased capacity to infect the brain because it preferentially
adhered to and invaded the unique endothelial cells that line the
blood vessels of central nervous system. To test this hypothesis, we
compared the interactions of this mutant with HUVECs and
HBMECs in vitro. We found that the adherence of the vps51D/D
mutant to HUVECs was increased by only 22% compared to the
wild-type strain (Figure 3A). However, the adherence of this
mutant to HBMECs was increased by 95% (Figure 3B). There was
an even greater difference in the capacity the vps51D/D mutant to
induce its own endocytosis by HUVECs compared to HBMECs.
The endocytosis of the vps51D/D mutant by HUVECs was 58%
lower than that of the wild-type strain (Figure 3C). In contrast, the
endocytosis of this mutant by HBMECs was 39% higher than the
wild-type strain (Figure 3D). Complementing the vps51D/D
mutant with an intact copy of VPS51 restored its interactions
with both types of endothelial cells to wild-type levels. The
Author Summary
During hematogenously disseminated infection, the fun-
gus Candida albicans is carried by the bloodstream to
virtually all organs in the body, including the brain. C.
albicans infection of the brain is a significant problem in
premature infants with disseminated candidiasis. To infect
the brain, C. albicans must adhere to and invade the
endothelial cells that line cerebral blood vessels. These
endothelial cells express unique proteins on their surface
that are not expressed by endothelial cells of other
vascular beds. Here, we show that C. albicans infects the
brain by binding to gp96, a heat shock protein that is
uniquely expressed on the surface of brain endothelial
cells. Gp96 is bound by the C. albicans Als3 invasin, which
induces the uptake of this organism by brain endothelial
cells. The C. albicans Ssa1 invasin also mediates fungal
uptake by brain endothelial cells, but does so by binding
to a receptor other than gp96. Thus, during hematoge-
nously disseminated infection, C. albicans traffics to and
infects the brain by binding to gp96, a receptor that is
expressed specifically on the surface of brain endothelial
cells.
C. albicans Invasion of Brain Endothelium
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invade HBMECs compared to HUVECs provides a likely
explanation for the enhanced tropism of this mutant for the brain.
Gp96 mediates C. albicans invasion of HBMECs
Next, we sought to identify the HBMEC receptor for both wild-
type C. albicans and the vps51D/D mutant. HBMECs are known to
express high amounts of the heat shock protein, gp96 on their cell
surface, whereas HUVECs do not [9]. Furthermore, gp96
functions as an HBMEC-specific receptor for E. coli K1 strains
that cause neonatal meningitis [9]. We used multiple complemen-
tary approaches to evaluate whether gp96 expression is required
for C. albicans to invade HBMECs. First, we tested the capacity of
an anti-gp96 antibody to inhibit HBMEC endocytosis of C.
albicans. This antibody reduced the endocytosis of wild-type C.
albicans by 24% and the vps51D/D mutant by 48% (Figure 4A).
Second, we determined the effects of siRNA-mediated knockdown
of gp96 on endocytosis. HBMECs transfected with gp96 siRNA
endocytosed 52% fewer wild-type C. albicans cells and 82% fewer
vps51D/D cells than did HBMECs transfected with control siRNA
(Figure 4B). Importantly, the effect of gp96 knockdown on
endocytosis was specific for HBMECs because knockdown of
gp96 in HUVECs had no effect on their capacity to endocytose C.
albicans (Figure 4C). Also, knockdown of gp96 did not inhibit
HBMECs endocytosis of transferrin (Figure 4D), demonstrating
that reducing gp96 protein levels did not cause a global decrease in
receptor-mediated endocytosis. Collectively, these results indicate
that gp96 is required for maximal HBMEC endocytosis of both
wild-type C. albicans and the vps51D/D mutant.
To further explore these findings, we investigated the effects of
overexpressing gp96 on the endocytosis of C. albicans. We found
that overexpression of gp96 in HBMECs enhanced the endocy-
tosis of the wild-type strain and the vps51D/D mutant by 100%
and 115%, respectively (Figure 4E). Similarly, heterologous
expression of human gp96 in Chinese hamster ovary (CHO) cells
resulted in a 42% increase in the endocytosis of wild-type C.
Figure 1. A vps51D/D mutant has attenuated overall virulence, but increased brain tropism during hematogenously disseminated
candidiasis. (A and B) Survival of mice after intravenous inoculation with 5610
5 (A) or 3610
6 (B) yeast phase cells of the indicated strains of C.
albicans (n=10 mice per strain). (C – E) Fungal burden of the kidneys (C), liver (D), and brain (E) of mice at the indicated times after inoculation with
5610
5 cells of the various strains. Results from days 1, 4, 7, 14, and 21 are median 6 interquartile range of a single experiment with 7 mice per strain
at each time point. Data from day 3 are the combined results from two experiments, each with 6–7 mice per strain. Only mice infected with the
vps51D/D mutant were analyzed at the 7, 14, and 21 day time points because all of the mice infected with the other C. albicans strains had died. At
these later time points, the absence of a bar indicates that the fungal burden was below the limits of detection. *p,0.01 compared to the wild-type
(WT) and vps51D/D+pVPS51 complemented strains by the Wilcoxon Rank Sum Test. (F). Histopathology of the hypothalamus of mice after 3 days of
infection with the indicated strains. Sections were stained with Gomori methenamine silver. Scale bar 10 mm. Arrows indicate the organisms.
doi:10.1371/journal.ppat.1002305.g001
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candidiasis. (A) Survival of mice after intravenous inoculation of with 3610
6 yeast phase cells of the indicated strains. 10 mice were infected with
each strain. (B) Increased brain fungal burden of mice 3 days after intravenous inoculation of 5610
5 cells per strain. Results are the median 6
interquartile ranges of 7 mice per strain. *p,0.01 compared to the wild-type and vps53D/D+pVPS53 complemented strains.
doi:10.1371/journal.ppat.1002305.g002
Figure 3. The vps51D/D mutant interacts differently with human umbilical vein endothelial cells (HUVECs) versus human brain
microvascular endothelial cells (HBMECs). (A and B) Adherence of germ tubes of the indicated C. albicans strains to HUVECs (A) and HBMECs (B).
(C and D) Endocytosis of hyphae of the indicated strains by HUVECs (C) and HBMECs (D). The results are expressed as a percentage of the wild-type
strain and are the mean 6 SD of 3 experiments, each performed in triplicate. The mean adherence of the wild-type strain to HUVECs and HBMECs was
47% and 28%, respectively. The mean number of wild-type cells endocytosed by HUVECs and HBMECs was 109 and 35 organisms per 10 high-
powered fields (HPF), respectively. *p,0.01 compared to both the wild-type strain and the vps51D/D+pVPS51 complemented strain by Analysis of
Variance.
doi:10.1371/journal.ppat.1002305.g003
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mutant compared to control CHO cells transfected with the
empty vector (Figure 4F). Therefore, these combined results
demonstrate that gp96 functions as an HBMEC receptor that
mediates the endocytosis of both wild-type C. albicans and the
vps51D/D mutant.
C. albicans Als3 and Ssa1 mediate HBMEC endocytosis in
vitro
Our previous studies revealed that the C. albicans proteins Ssa1
and Als3 function as invasins that induce the endocytosis of this
organism by HUVECs [14,15]. To investigate the roles of these
fungal proteins in HBMEC invasion, we analyzed ssa1D/D and
als3D/D single mutants, as well as vps51D/D ssa1D/D and vps51D/
D als3D/D double mutants. Approximately 30% fewer hyphae of
the ssa1D/D single mutant were endocytosed by HBMECs as
compared to wild-type parent strain and the ssa1D/D+pSSA1
complemented strain (Figure 5A). Similarly, the endocytosis of the
vps51D/D ssa1D/D double mutant was significantly lower than the
vps51D/D single mutant. Thus, Ssa1 is required for the maximal
endocytosis of both wild-type and vps51D/D mutant strains of C.
albicans by HBMECs in vitro.
Als3 played a greater role than Ssa1 in stimulating the
endocytosis of C. albicans by HBMECs in vitro. Both the als3D/D
single mutant and the vps51D/D als3D/D double mutant were
endocytosed extremely poorly by these endothelial cells
(Figure 5B), indicating that Als3 is essential for the endocytosis
of C. albicans by HBMECs in vitro.
To determine whether Ssa1 and Als3 mediate the endocytosis of
C. albicans by directly interacting with endothelial cells, we used a
heterologous expression strategy in which we expressed C. albicans
SSA1 or ALS3 in the normally non-invasive yeast, Saccharomyces
cerevisiae [25]. Expression of C. albicans SSA1 in S. cerevisiae resulted
in a 300% increase in the endocytosis of this organism by
HUVECs and a 43% increase in its endocytosis by HBMECs, as
compared to the control strain of S. cerevisiae (Figure 6A and B).
Moreover, expression of C. albicans ALS3 in S. cerevisiae resulted in a
2050% and 1880% increase in endocytosis by HUVECs and
HBMECs, respectively (Figures 6C and D). Collectively, these
data demonstrate that Ssa1 is a more potent inducer of fungal
endocytosis by HUVECs than by HBMECs, whereas Als3 can
induce endocytosis by HUVECs and HBMECs with similar
efficacy. As HUVECs do not express gp96 on their surface [9],
HUVEC endocytosis of S. cerevisiae expressing C. albicans SSA1 or
Figure 4. C. albicans endocytosis by HBMECs is mediated by gp96. (A) Reduced HBMEC endocytosis of wild-type and vps51D/D mutant strains
of C. albicans by an anti-gp96 antibody. (B and C) Knockdown of gp96 by siRNA inhibits the endocytosis of C. albicans by HBMECs (B), but not by
HUVECs (C). (D) Gp96 knockdown has no effect on transferrin endocytosis by HBMECs. (E and F) Overexpression of human gp96 in HBMECs (E) and
Chinese Hamster Ovary (CHO) cells (F) results in increased endocytosis of C. albicans. The results are expressed as a percentage of the wild-type strain
and are the mean 6 SD of 3 experiments, each performed in triplicate. The mean number of wild-type cells endocytosed by control HBMECs, HUVECs,
and CHO cells was 41, 49, and 48 organisms per 10 HPF, respectively. *p,0.01 compared to control strains. Images to the right of the graphs are of
representative immunoblots showing the effects of the interventions on total gp96 and b-actin protein levels in the cells.
doi:10.1371/journal.ppat.1002305.g004
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cadherin and HER2 [14–17].
Als3 interacts with gp96 to induce HBMEC endocytosis
The above results suggested a model in which Als3 on the surface
of C. albicans hyphae binds to gp96 on the surface of HBMECs and
induces endocytosis. To test this model, we analyzed the effects of
siRNA knockdown on the endocytosis of the S. cerevisiae strain that
expressed C. albicans Als3. As predicted, knockdown of gp96 in
HBMECs reduced the endocytosis of the Als3 expressing strain of S.
cerevisiae by 79% compared to control HBMECs (Figure 6E).
We also tested the capacity of different C. albicans mutants and
strains of S. cerevisiae to bind gp96 in HBMEC membrane protein
extracts. As predicted by our endocytosis results, the vps51D/D
mutant bound more gp96 than did the wild-type strain (Figure 7A).
Also, the ssa1DD mutant bound slightly less gp96 than did the wild-
type strain, and the als3D/D mutant bound very poorly to this
protein. Finally, the strain of S. cerevisiae that expressed C. albicans
Als3 bound to gp96, whereas the control strain of S. cerevisiae did not
(Figure 7B), thus indicating that Als3 directly interacts with gp96.
Next, we used flow cytometric analysis of C. albicans hyphae
stained with either anti-HSP70 or anti-Als3 antibodies to quantify
the levels of Ssa1 and Als3 that were exposed on the surface of the
various strains. Although the vps51D/D mutant had normal Ssa1
surface exposure (data not shown), it had greater surface exposure
of Als3 than did the wild-type and vps51D/D+pVPS51 comple-
mented strains (Figure 7C). The greater surface exposure of Als3
by the vps51D/D mutant likely contributes its enhanced capacity to
induced HBMEC endocytosis.
Ssa1 is important for brain invasion by wild-type C.
albicans whereas Als3 is necessary for brain invasion by
the vps51D/D mutant
Lastly, we investigated the roles of Ssa1 and Als3 in mediating
brain invasion in vivo by both wild-type and vps51D/D mutant
strains of C. albicans. Mice were inoculated with the various C.
Figure 5. Deletion of SSA1 or ALS3 reduces HBMEC endocytosis of C. albicans. (A and B) Endocytosis of the indicated strains of C. albicans by
HBMECs. The results are expressed as a percentage of the wild-type strain and are the mean 6 SD of 3 experiments, each performed in triplicate. A
mean 65 of wild-type cells per HPF was endocytosed by the HBMECs. *p,0.01 compared to the wild-type strain; {p,0.01 compared to the vps51D/D
mutant.
doi:10.1371/journal.ppat.1002305.g005
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determined 3 days later. Similar to our previous results [14], the
brain fungal burden of mice infected with the ssa1D/D single
mutant was significantly less than that of mice infected with either
the wild-type strain or the ssa1D/D+pSSA1 complemented strain
(Figure 8A). However, the brain fungal burden of mice infected
with the vps51D/D ssa1D/D double mutant was only 1.7-fold lower
than that of mice infected with the vps51D/D single mutant, a
difference that did not achieve statistical significance (p=0.053).
Taken together, these results indicate that Ssa1 is necessary for
wild-type C. albicans to cause maximal brain infection, but that it
plays a relatively minor role in enhanced brain tropism of the
vps51D/D mutant.
Different results were obtained with strains that lacked Als3.
The brain fungal burden of mice infected with the als3D/D single
mutant was similar to that of mice infected with the wild-type
strain (Figure 8B). In contrast, mice infected with the vps51D/D
als3D/D double mutant had 5.5-fold fewer organisms in their
brain compared to mice infected with the vps51D/D single mutant.
Therefore, although Als3 is dispensable for wild-type C. albicans to
Figure 6. Both Als3 and Ssa1 induce HBMEC endocytosis, but Als3 has a greater effect than Ssa1. (A and B) Endocytosis by HUVECs (A)
and HBMECs (B) of S. cerevisiae expressing C. albicans SSA1, or the backbone vector (control). (C and D) Endocytosis by HUVECs (C) and HBMECs (D) of
S. cerevisiae expressing C. albicans Als3 or the backbone vector (control). (E) Effect of siRNA knockdown of gp96 on HBMEC endocytosis of S. cerevisiae
expressing C. albicans ALS3. Image on the right is of a representative immunoblot of total HBMEC lysates probed for gp96 and b-actin. The
endocytosis data are the mean 6 SD of 3 experiments, each performed in triplicate. The results in (A–D) are expressed as a percentage of the control
strain containing the backbone vector and the results in (E) are expressed as a percentage of the endocytosis of the ALS3 expressing strain by HBMEC
transfected with control siRNA. The mean number of control cells endocytosed by the HUVECs and HBMECs in (A–D) was 3.2 and 1.2 organisms per
10 HPF, respectively. A mean of 49 cells of the Als3 expressing strain per HPF was endocytosed by HBMEC transfected with the control siRNA in (E).
*p,0.01 compared to control strains.
doi:10.1371/journal.ppat.1002305.g006
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maximal brain fungal burden.
Discussion
In the mouse model of disseminated candidiasis, kidney fungal
burden is directly correlated with mortality [23,26]. Thus, many
studies of this disease have used kidney fungal burden as the
primary endpoint when analyzing either the virulence of mutant
strains of C. albicans in mice or the susceptibility of mutant strains
of mice to disseminated candidiasis [27–31]. However, during
disseminated candidiasis in both mice and humans, C. albicans
infects virtually all organs in the body. To do so, the blood-borne
organisms must adhere to and invade the vascular beds of these
organs. Importantly, there are significant differences among the
endothelial cells that line the vasculature of the different organs, as
well as the immunologic milieu of these organs [32,33]. These
differences provide a compelling rationale to investigate the
capacity of C. albicans to traffic to and persist in organs other than
the kidney. The brain is a particularly important target organ in
neonates with hematogenously disseminated candidiasis [4,5], and
its blood vessels are lined with the unique endothelial cells that
form the blood-brain barrier. Our studies with a vps51D/D mutant
strain of C. albicans led us to discover that C. albicans traffics to the
brain and invades cerebral blood vessels in part by binding to gp96
that is expressed on the surface of brain endothelial cells.
We had previously identified C. albicans VPS51 through a
microarray study that was designed to discover genes that were up-
regulated when the organism adhered to HUVECs [20]. In that
study, we determined that a vps51/vps51 insertion mutant had
reduced capacity to damage HUVECs and increased susceptibility
to antimicrobial peptides [20]. These in vitro findings led us to
predict that VPS51 would be required for the maximal virulence of
C. albicans during disseminated disease. In the current study, we
verified this prediction by determining that mice infected with a
vps51D/D deletion mutant had no mortality and progressively
cleared this strain from their kidneys and liver.
A unique and unexpected phenotype of the vps51D/D mutant
was its marked propensity to infect the brain. In the few previous
studies in which the brain fungal burden of mice infected with
mutant strains of C. albicans was determined, the fungal burden in
the brain generally paralleled the fungal burden in the kidney. For
example, mice infected with ecm33D/D and hog1D/D mutants had
improved survival and reduced fungal burden in both the kidney
and the brain, as compared to mice infected with the wild-type
strain [34,35]. Thus, it was unusual to find that mice infected with
the vps51D/D mutant had reduced kidney fungal burden, yet
significantly increased brain fungal burden.
Our finding that the enhanced capacity of the vps51D/D mutant
to adhere to and invade HBMECs, as compared to HUVECs,
provides a likely explanation for its brain tropism. One difference
between HBMECs and HUVECs is that the former cells express
gp96 on their surface, whereas the latter cells do not [9]. Multiple
lines of evidence indicate that gp96 functions as an HBMEC
receptor for both wild-type C. albicans and the vps51D/D mutant.
For example, an anti-gp96 antibody and siRNA knockdown of
gp96 inhibited HBMEC endocytosis of C. albicans. Furthermore,
overexpression of gp96 in HBMEC and the heterologous
expression of human gp96 in CHO cells increased the endocytosis
of C. albicans. Finally, wild-type C. albicans cells bound to gp96 in
extracts of HBMEC membrane proteins, and the highly
endocytosed vps51D/D mutant bound even more of this protein.
Collectively, these data indicate that gp96 is an HBMEC receptor
for C. albicans.
It was notable that in both the anti-gp96 antibody studies and
the gp96 siRNA experiments, inhibition of gp96 function or
expression had greater effect on the endocytosis of the vps51D/D
mutant than the wild-type strain (78% reduction for the vps51D/D
mutant vs. 38% reduction for the wild-type strain; p,0.0001).
These results indicate that the vps51D/D mutant preferentially
utilizes gp96 as a receptor to invade HBMECs. They further
suggest that the enhanced brain tropism of the vps51D/D mutant is
likely due to its increased binding to gp96 on the surface of brain
endothelial cells.
Although these results strongly indicate that gp96 is important
for HBMEC endocytosis of C. albicans, the findings that neither the
anti-gp96 antibody nor siRNA knockdown of gp96 completely
blocked the endocytosis of this organism suggest that it can invade
HBMECs by additional mechanisms. Such mechanisms include
the induction of endocytosis by binding to one or more receptors,
such as N-cadherin that are independent of gp96 and active
penetration, in which hyphae physically push their way into host
cells by progressively elongating [16,36].
Because gp96 also functions as a molecular chaperone [37], it is
possible that it could be involved in the endocytosis of C. albicans by
altering the expression or function of other proteins on the surface
of HBMECs. Our data indicate that this possibility is remote
because HBMEC endocytosis of C. albicans was inhibited by the
Figure 7. Effects of deletion of VPS51, SSA1, and ALS3 on
binding to gp96 and fungal surface expression of Als3. (A and B)
Immunoblots of HBMEC membrane proteins that were bound by the
indicated strains of C. albicans (A) or S. cerevisiae (B). Both blots were
probed with an anti-gp96 antibody. (C) Flow cytometric analysis of Als3
exposure on the surface of hyphae of the wild-type, vps51D/D mutant,
and vps51D/D+pVPS51 complemented strains.
doi:10.1371/journal.ppat.1002305.g007
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function of gp96. In addition, siRNA knockdown of gp96 inhibited
the endocytosis of C. albicans by HBMECs, but not HUVECs, in
which gp96 is located intracellularly. Moreover, gp96 knockdown
did not affect transferrin uptake in HBMECs, a process that is
mediated by the transferrin receptor. Thus, the role of gp96 in
inducing the endocytosis of C. albicans is likely due to its function as
a cell surface receptor rather than a chaperone.
Gp96 has been reported to be expressed on the surface of some
epithelial cells where it functions as a receptor for Listeria
monocytogenes, Neisseria gonorrhoeae and bovine adeno-associated virus
[38–40]. In addition, gp96 on the surface of HBMEC is known to
be bound by E. coli K1 OmpA [9]. This binding induces the
endocytosis of E. coli by activating signal transducer and activator
of transcription 3 (STAT3), which functions upstream of
phosphatidylinositol-3 kinase and protein kinase C-a [41–43].
Whether the binding of C. albicans to gp96 activates a similar
signaling pathway remains to be determined.
C. albicans possesses at least two invasin-like proteins, Ssa1 and
Als3. Both of these proteins induce the endocytosis of C. albicans by
HUVECs by binding to N-cadherin and other endothelial cell
receptors [14,15]. These two invasins may function cooperatively
because the endocytosis defect of an ssa1D/D als3D/D double
mutant is not greater than that of an als3D/D single mutant [14].
Our current studies with the C. albicans ssa1D/D and als3D/D
mutants and strains of S. cerevisiae that overexpress C. albicans Ssa1
and Als3 demonstrate that both of these proteins can induce
HBMEC endocytosis. The results of these in vitro experiments also
indicate that Als3 is more important than Ssa1 in inducing
HBMEC endocytosis, probably because it plays a greater role in
binding to gp96.
Our mouse studies suggest that Ssa1 is required for the maximal
trafficking of wild-type C. albicans to the brain because the brain
fungal burden of mice infected with the ssa1D/D mutant was
significantly less than that of mice infected with the wild-type
strain. These results are similar to our previous data [14].
However, deletion of SSA1 in the vps51 mutant had only a minor
effect on brain trafficking. It is probable that in the vps51D/D
mutant, the effects of deleting SSA1 were masked by the increased
surface expression of Als3.
A paradoxical finding was that although the endocytosis of the
als3D/D mutant by HBMECs was severely impaired in vitro, this
Figure 8. Deletion of SSA1 and ALS3 have different effects on brain fungal burden. (A and B) Brain fungal burden of mice after 3 days of
infection with the indicated strains of C. albicans. Results are median 6 interquartile ranges of 7 mice per strain. *p,0.02 compared to mice infected
with the wild-type strain;
{p,0.001 compared to mice infected with the vps51D/D mutant.
doi:10.1371/journal.ppat.1002305.g008
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virulence of an als3D/D mutant in the mouse model of
disseminated candidiasis has recently been reported by others
[44]. It is unclear why there is such a large discrepancy between
the host cell interactions of the als3D/D mutant in vitro and its
virulence in mice, especially because ALS3 is highly expressed in
vivo [45,46]. The most probable explanation for these paradoxical
results is that other invasins, such as Ssa1 and perhaps other
proteins, compensate for the absence of Als3. Because the in vitro
experiments were performed using human endothelial cells and
the virulence experiments were performed in mice, it is
theoretically possible that differences between human and mouse
gp96 may account for the differences between the in vitro and in vivo
results. However, human and mouse gp96 are 97.5% identical at
the amino acid level, making this possibility unlikely.
Importantly, our results indicate that Als3 does play a role in the
enhanced brain tropism of the vps51D/D mutant because the brain
fungal burden of mice infected with vps51D/D als3D/D double
mutant was significantly lower than that of mice infected with the
vps51D/D single mutant. Because protein trafficking is likely
abnormal in the vps51D/D mutant, we speculate that this strain
has reduced expression of compensatory proteins in response to
deletion of ALS3. On the other hand, the vps51D/D als3D/D
double mutant still had greater tropism for the brain compared to
the wild-type strain. This result suggests that the overexpression of
additional proteins, other than Als3, contributes to the brain
tropism of the vps51D/D single mutant.
The combined results of these experiments support a model in
which C. albicans invades the brain during hematogenously
disseminated infection by binding to proteins that are specifically
expressed on the surface of brain endothelial cells. One of these
proteins is gp96, which is bound predominantly by C. albicans Als3
(Figure 9). At least one other brain endothelial cell protein
functions as receptors for C. albicans Ssa1. As the endothelial cells
of other vascular beds also express unique surface proteins, it is
highly probable that blood-borne C. albicans utilizes different
endothelial cell surface proteins to infect different organs.
Identification of these organ-specific receptors for C. albicans may
lead to novel approaches to block these receptors and thereby
prevent hematogenous dissemination.
Materials and Methods
Fungal strains and plasmids
The fungal strains used in this study are listed in Supplemental
Table S1. All C. albicans mutant strains constructed for this study
were derived from strain BWP17 [47]. Deletion of the entire
protein coding regions of both alleles of VPS51 was accomplished
by successive transformation with ARG4 and HIS1 deletion
cassettes that were generated by PCR using the oligonucleotides
vps51-f and vps51-r (The oligonucleotide sequences are listed in
Supplemental Table S2) [47]. The resulting strain was subse-
quently transformed with pGEM-URA3 [47] to re-integrate URA3
at its native locus. The vps53D/D mutant was constructed
similarly, using the oligonucleotides vps53-f and vps53-r. To
construct the VPS51 complemented strain (vps51D/D+pVPS51), a
2.6 Kb fragment containing VPS51 was generated by high fidelity
PCR with the primers vps51-rev-f and vps51-rev-r using genomic
DNA from C. albicans SC5314 as the template. This PCR
product was digested with NcoI, and then subcloned into pBSK-
Ura, which had been linearized with NcoI. The resulting construct
was linearized with NotI and PstI to direct integration at the
URA3 locus of a Ura
– vps51D/D mutant strain. The vps53D/D-
complemented strain (vps53D/D+pVPS53) was generated similarly,
except that primers vps53-rev-f and vps53-rev-r were used to PCR
amplify a 3.3 Kb DNA fragment containing VPS53.
To delete the entire protein coding region of ALS3 in the
vps51D/D mutant, deletion cassettes containing ALS3 flanking
regions and the URA3 or NAT1 selection markers were amplified
by PCR with primers als3-pgem-KO-f and als3-pgem-KO-r, using
pGEM-URA3 [47] and pJK795 [48] as templates, respectively.
These PCR products were then used to successively transform a
Ura- ssa1D/D strain. The resulting als3D/D vps51D/D double
mutant was plated on 5-fluoroorotic acid to select for a Ura- strain,
which was then transformed with pGEM-URA3 as above. The
als3D/D vps51D/D+pVPS51 complemented strain was generated
the same way as was the vps51D/D+pVPS51 complemented strain.
The ssa1D/D vps51D/D double mutant and its VPS51-comple-
mented strain (ssa1D/D vps51D/D+pVPS51) were generated
similarly to the als3D/D vps51D/D double mutant and its
complemented strain, except that primers ssa1-pgem-f and ssa1-
pgem-r were used to amplify the SSA1 deletion cassettes.
The construction of the S. cerevisiae strain that expressed C.
albicans ALS3 under the control of the ADH1 promoter and its
control strain containing the backbone vector was described
previously [25]. To express C. albicans SSA1 in S. cerevisiae, a 2.0 kb
fragment containing the SSA1 protein coding region was generated
by PCR with primers ssa1-exp-bglii-f and ssa1-exp-xhoi-r using
pRP10-SSA1ORF as template [49]. The resulting SSA1 fragment
was cloned downstream of the GAL1 promoter of pYES2.1/V5-
His-TOPO using the pYES2.1 TOPO TA Expression Kit
(Invitrogen) following the manufacturer’s instructions. The control
Figure 9. Model of the receptor-ligand interactions that mediate the endocytosis of C. albicans by HBMECs. C. albicans Als3 binds to
gp96 on the surface of HBMECs and induces endocytosis. C. albicans Ssa1 binds to an HBMEC surface protein other than gp96, which also induces
endocytosis. PM, plasma membrane.
doi:10.1371/journal.ppat.1002305.g009
C. albicans Invasion of Brain Endothelium
PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002305strain of S. cerevisiae was transformed with the backbone vector
alone. Expression of C. albicans SSA1 was induced by growth in SC
minimal medium containing 2% galactose following the manu-
facturer’s protocol.
Murine model of disseminated candidiasis
Male BALB/c mice weighing 18–20 g (Taconic Farms) were
used for all animal experiments. For survival studies, 10 mice per
strain were injected via the tail vein with either 5610
5 or 3610
6
yeast of the various C. albicans strains [50] and then monitored for
survival three times daily. All inocula were confirmed by colony
counting. In the organ fungal burden studies, the mice were
inoculated with 5610
5 yeast as above. At various time points, 7
mice per strain were sacrificed and the kidney, liver, and brain
were harvested. These organs were weighed, homogenized and
quantitatively cultured. For histopathological analysis, a portion of
the excised tissue was fixed in zinc-buffered formalin followed by
70% ethanol. The tissue was then embedded in paraffin, after
which thin sections were prepared and stained with Gomori
methenamine silver. They were examined by light microscopy. All
mouse experiments were approved by the Animal Care and Use
Committee at the Los Angeles Biomedical Research Institute and
carried out according to the National Institutes of Health (NIH)
guidelines for the ethical treatment of animals.
Endothelial cells
HUVECs were harvested from umbilical cords with collagenase
and grown in M-199 medium supplemented with 10% fetal bovine
serum and 10% defined bovine calf serum (Gemini Bio-Products),
and containing 2 mM L-glutamine with penicillin and streptomy-
cin (Irvine Scientific) as previously described [51]. HBMECs were
isolated from the capillaries in small fragments of the cerebral
cortex, which were obtained by surgical resection from 4- to 7-
year-old children with seizure disorders at Children’s Hospital Los
Angeles. HBMECs were harvested from these capillaries and
maintained in a mixture of M-199 and Ham’s F-12 media (1:1 v/
v) supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, and 2 mM glutamine as described previously [52]. More
than 98% of these cells were positive for Factor VIII-rag and
carbonic anhydrase, and negative for GFAP by flow cytometry. In
addition, 99% of the cells took up Dil-Ac-LDL by immunocyto-
chemistry. CHO K-1 cells expressing human gp96 were generated
and grown as outlined before [9]. All cell types were grown at
37uCi n5 %C O 2.
Knockdown of gp96 by siRNA
HBMECs or HUVECs were grown to 60% confluence in six-
well plates, then transfected with either gp96 siRNA (Catalog
number HSS110955; Invitrogen) or a random control siRNA
using lipofactamine 2000 (Invitrogen), according to the manufac-
turer’s instructions. Gp96 knockdown was verified by Western
blotting of total endothelial cell lysates with an anti-gp96
monoclonal antibody (Santa Cruz Biotechnology).
Affinity purification of gp96 using intact organisms
HBMEC membrane proteins from host cells were isolated using
octyl-glucopyranoside exactly as described previously [16]. Next,
2610
8 hyphae of the various C. albicans strains or 8610
8 yeast of
the different S. cerevisiae strains were incubated on ice for 1 h with
250 mg of HBMEC membrane proteins in PBS with calcium and
magnesium and containing 1.5% octyl-glucopyranoside and
protease inhibitors. The unbound proteins were removed by
extensive rinsing in the same buffer. Next, the proteins that had
bound to the hyphae were eluted with 6M urea. The eluted
proteins were separated by SDS-PAGE and detected by
immunoblotting with the anti-gp96 antibody using enhanced
chemiluminescence (Pierce).
Candidal adherence
The adherence of C. albicans to HUVECs and HBMECs grown
in 6-well tissue culture plates was measured by a modification of
our previously described method [25]. Briefly, germ tubes of the
various strains were generated by a 1-h incubation in RPMI 1640
medium (Irvine Scientific) at 37uC. The germ tubes were
enumerated with a hemacytometer and suspended in HBSS at
200 cells/ml. After rinsing the endothelial cell monolayers twice
with HBSS, 1 ml of the germ tube suspension was added to each
well. The cells were incubated for 30 min, after which the
nonadherent organisms were aspirated and the endothelial cell
monolayers were rinsed twice with HBSS in a standardized
manner. Next, the wells were overlaid with YPD agar and the
number of adherent organisms was determined by colony
counting. The adherence results were expressed as a percentage
of the initial inoculum, which was verified by quantitative culture.
Each strain was tested in triplicate on three different days.
Candidal endocytosis
The number of organisms internalized by the endothelial cells
was determined using our standard differential fluorescence assay
[15,16]. Briefly, endothelial cells on glass coverslips were infected
with 10
5 yeast phase cells of each strain of C. albicans in RPMI
1640 medium. After incubation for 3 h, the cells were fixed with
3% paraformaldehyde. The noninternalized cells were stained
with anti-C. albicans rabbit serum (Biodesign International) that
had been conjugated with Alexa 568 (Invitrogen). Next, the
endothelial cells were permeablized in 0.1% (vol/vol) Triton X-
100 in PBS, after which both the internalized and the
noninternalized organisms were stained with anti-C. albicans rabbit
serum conjugated with Alexa 488 (Invitrogen). The coverslips were
mounted inverted on a microscope slide and viewed under
epifluorescence. The number of organisms endocytosed by the
endothelial cells was determined by subtracting the number of
noninternalized organisms (which fluoresced red) from the total
number of organisms (which fluoresced green). At least 100
organisms were counted on each coverslip, and all experiments
were performed in triplicate on at least three separate occasions.
Transferrin uptake
HBMECs were grown to 70% confluency in 6-well tissue
culture plates and then incubated for 3 in serum-free medium to
deplete endogenous transferrin. Next they were incubated for
45 min in serum-free medium containing AlexaFluor 555-labeled
transferrin (Invitrogen; 10 mg/ml). The unincorporated transferrin
was removed by rinsing, after which the cells were incubated for
an additional 30 min. Any remaining surface bound transferrin
was removed by rinsing the cells twice with ice-cold PBS
containing Ca
++ and Mg
++ (PBS
++) followed by two, 5 min
incubations with ice-cold acid wash buffer (0.2 M acetic acid
(pH 2.8) 0.5 M NaCl). Finally, the cells were washed three times
with ice-cold PBS
++, detached with Cell Dissociation Buffer
(Invitrogen), and suspended in PBS
++. Their transferrin content
was determined by flow cytometry, analyzing at least 10,000 cells.
Flow cytometry
Flow cytometry was used to analyze the surface expression
Als3p on hyphae of the various strains using a minor modification
C. albicans Invasion of Brain Endothelium
PLoS Pathogens | www.plospathogens.org 11 October 2011 | Volume 7 | Issue 10 | e1002305of our previously described method [14]. Briefly, hyphae of the
different strains of C. albicans were fixed in 3% paraformaldehyde
and blocked with 1% goat serum. The hyphae were then
incubated with either a rabbit polyclonal antiserum raised against
rAls3-N or purified rabbit IgG. After extensive rinsing, the cells
were incubated with a goat anti-rabbit secondary antibody
conjugated with Alexa 488. The fluorescent intensity of the
hyphae was measured by flow cytometry. Fluorescence data for
10,000 cells of each strain were collected.
Statistical analyses
The capacity of the various strains of C. albicans and S. cerevisiae
to adhere to, and be endocytosed to endothelial cells was
compared using analyses of variance. Differences in the fungal
burden of mice infected with these strains were analyzed using the
Wilcoxon Rank Sum test. Differences in survival were analyzed
using the Log-Rank test.
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